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s. It is estimated that the cost of medi- 
cations is about 6% of the total health care cost in this country. 
Rhetoric that suggests, thcrcforc, that the pharmaceutical 
industry itself is responsible for the burgeoning increase in 
medical costs is obviously mislca ing. It is clear, howcvcr. that 
dramatic changes in pricing arc reducing even this small 
segment of medical cart costs. Consortia buyers and formulaly 
committees have apparently adopted price as the single or, at 
the very Icast, ovelwhcltning determinant of which drugs will 
he available to patients. If our own formulary committee is 
reprcscntative of others, it appears that price alone is used 
over issues such as approved indications, pharmacokinetic 
differences and drug-specific other than class effects. Generic 
substitutions arc the rule, and in many locales pharmacists may 
freely substitute “equivalent” drugs with disregard for subtle or 
not so subtlc pharmacologic differences. Since drugs that 
contain identical product and dose are considered to be 
equivalent, generic substitution is used even though bioequiva- 
lcncc may bc quite different. Note that drugs available before 
the 1938 Food, Drug and Cosmetic Act can be marketed 
without Food and Drug Administation (FDA) approval. How- 
ever, this does not ensure bioequivalence, as was noted, for 
example, in a study of four different digoxin tablets (1) and 
different preparations of lcvothyroxine (2). This experience 
should rightly concern the physician who expects a certain 
response from a specific medication. 
Profits. The second issue relates to the profits of the 
pharmaceutical industry. In a free market economy, we gener- 
ally applaud large companies that make products that meet the 
Address for correspondence: William W. Parmley. MD, Editor-in-Chief. 
Joun~ul offlx Awbur College ofCnrdio&v, 415 Judah Street, San Francisco, 
California 94122. 
tests of competition, consumer satisfaction and rigorous man- 
ufacturing standards. In addition, available products of the 
~~~l~~~l~~~cc~tic~~~ industry have met A standards of safety and 
cflicacy. The c’normous costs of cc ch and development and 
the short patent life put additional pressures on the 
ceutical industry that are not imposed on other in 
Current economic pressures on many industries, including the 
pharmaceutical Companies, have led to cost cutting, down- 
sizing and restructuring. Pharmaceutical companies are not 
immune from the market pressures of a free economy. It 
appears to me that attacks on the profits of pharmaceutical 
companies are often politically motivated and designed to fuel 
the fire of a specific cost-cutting health care agenda. Such 
invective is better spent on the tobacco industry, whose cnor- 
mous profits are bought at the expense of the premature death 
of I hundred thousand Americans each year. 
~dv~~isin~, The issue of potentially misleading ad- 
vertising was raised, for example, in an article and editorials in 
the Aatzab of Itzteml Medicitze (3-5). In the article, 109 ad- 
vertisements representing 103 different products were evalu- 
ated in 11 specialty areas by three expert reviewers. Reviewers 
felt that the information was not balanced in 40% and that the 
headlines misled the reader in 32% of advertisements. How- 
ever, reviewers agreed with safety claims in 86% of ads, and 
there was considerable disagreement between reviewers on 
other items they were asked to consider. The differences 
between reviewers seemed to be about the same magnitude as 
we see in the peer-reviewed articles submitted to JACC. TO 
some extent, the ads we see in the Journal may be a product of 
the advertising companies rather than the pharmaceutical 
companies. If anything, they seem much more restrained than 
most ads that we see for other products in magazines and on 
television. 
Influence on physicians. There has been concern that phy- 
sicians arc unduly influenced by drug companies. For example, 
a recent article (6) pointed out that many symposia sponsored 
directly or indirectly by pharmaceutical companies end up as 
supplements in medical journals that may concentrate h avily 
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on a given drug and present an unbalanced picture. To avoid 
this at JACC, we have not accepted such symposia, which 
ultimately have only one sponsor. Such concerns have led to a 
change ineducational programs, which are now categorized as 
either promotional or educational. Despite these potential 
problems, however, physicians seem to be quite aware of the 
possibility of bii in programs sponsored by pharmaceutical 
companies. I’m not sure that we give physicians enough credit 
for their ability to recognize bias and thus effectively filter out 
slanted information. In any event, changes over the past 
several years have reduced the potential problem of undue 
inthtence. The American Medical Association guidelines on 
gifts from industry to physicians (7) are a good example. 
Similarly, the policy statement on American College of Cardi- 
industry guidelines also clearly spells out appropriate 
ways that industry can support educational ctivities. The 
bequest of unrestricted funds to support educational activities 
is one of the best examples of a beneficial partnership between 
medicine and the pharmaceutical companies. Full disclosure of 
conflicts of interest in journal articles and at educational 
programs is another healthy step toward defusing this issue. 
No one denies that the pharmaceutical companies have 
faults (as does the medical establishment). However, it appears 
to me that some voices have been too harsh in their criticism. 
At a time when all of medicine is under attack, I believe that 
we are better served by maintaining a healthy and appropriate 
partnership with the pharmaceutical industry. Certainly, many 
of our best educational activities, such as the annual meeting, 
require that continued support. Above all, we must have a 
healthy pharmaceutical industry to maintain the pipeline of 
drugs that improve the quality of life and reduce morbidity and 
mortality. 
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